摘要
背景与目的 近年来,放疗联合化疗的综合治疗已取代单纯放疗成为不能手术的局部晚期 NSCLC的标准治疗方法。本研究拟在比较两周期诱导化疗后Ⅲ期非小细胞肺癌(NSCLC)同步放化疗与单 纯放疗的临床疗效和毒性反应。方法 将92例经过两周期以顺铂(DDP)为主诱导化疗后的Ⅲ期NSCLC患 者(ⅢA期26例,ⅢB期66例)随机分组,其中47例进入同步放化疗组,45例进入单独放疗组。同步放化疗 组化疗方案:异长春花碱(NVB)15~18mg/m2第1、8天,DDP60mg/m2第1天;放射治疗从第1天开始, 6MV X射线照射,二野等中心照射DT40Gy/4~4.5周后缩野,追加剂量至DT60~65Gy/6~6.5周。单独 放疗组:放射治疗方案同同步放化疗组。结果 所有患者均顺利完成治疗。同步放化疗组完全缓解率(CR) 为14.9%,部分缓解率(PR)为44.7%,单独放射治疗组CR6.7%,PR44.4%,两组的CR有显著性差异(P< 0.05),而有效率无显著性差异(P>0.05)。同步放化疗组的1、2年生存率分别为65.9%、42.5%,单独放疗 组为53.3%、33.3%,无显著性差异(P>0.05)。同步放化疗组的1、2年局控率分别为63.8%、53.2%,单独 放疗组为51.1%、44.4%,有显著性差异(P<0.05)。同步放化疗组Ⅲ+Ⅳ级的放射性食管炎和白细胞下降 发生率分别为21.2%和12.
Background and objective Recently chemoradiotherapy becomes a standard treatment of un-resectable advanced non-small cell lung cancer (NSCLC) instead of radiotherapy alone. This study is to evaluate the clinical effect and toxicities of concurrent chemoradiotherapy in patients with stage Ⅲ NSCLC after 2 cycles of induction chemotherapy with cisplatin-based regimens. Methods Ninety-two patients with stage Ⅲ NSCLC were divided randomly into two groups: forty-seven patients received concurrent chemoradiotherapy (chemoradiotherapy group), the other 45 patients received only radiotherapy (radiotherapy group). For both groups, the same radiation technic was given with the conventional fraction. The total dose was 60--65Gy/30--33Fr/6--6.5Wk. For the chemoradiotherapy group, the patients were also given with concurrent chemotherapy (navelbine 15--18mg/m 2 on the 1st and 8th day, cisplatin 60mg/m 2 on the 1st day). Results The response rate in the chemoradiotherapy group was similar to that in the radiotherapy group (59.6% vs 51.5%, P> 0.05), but the complete response rate in the chemoradiotherapy group was significantly higher than that in the radiotherapy group (14.9% vs 6.7%, P<0.05). The 1- and 2-year survival rates in the chemoradiotherapy group were similar to those in the radiotherapy group (65.9% and 42.5% vs 53.3% and 33.3%, P> 0.05). The 1- and 2-year local control rates in the chemoradiotherapy group were significantly higher than those in the radiotherapy group (63.8% and 53.2% vs 51.1% and 44.4%, P<0.05). The incidences of grade Ⅲ-Ⅳ radiation esophagitis and leukopenia in the chemoradiotherapy group were significantly higher than those in the radiotherapy group (21.2% and 12.7% vs 4.4% and 0, P<0.01). Conclusion Concurrent chemoradiotherapy has the potential of improving the survival rate of stage Ⅲ NSCLC, it can also increase the acute toxic effect, but all patients can tolerate this treatment regimen.
出处
《中国肺癌杂志》
CAS
2005年第1期48-50,共3页
Chinese Journal of Lung Cancer
关键词
非小细胞肺癌
放射治疗
化疗/同步放化疗
Non-small cell lung cancer Radiotherapy Chemotherapy/concurrent chemoradiotherapy